All In Biotech

NDA 215309 · Incyte Corp

Opzelura

Ruxolitinib Phosphate · Topical

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Sep 21, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

453

74 Phase 3, 109 recruiting

FAERS reports

15,313

10,796 serious, 2,698 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, AND THROMBOSIS SERIOUS INFECTIONS Patients treated with oral Janus kinase inhibitors for inflammatory conditions are at risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Invasive fungal infections, including cryptococcosis, and pneumocystosis. Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens. Avoid use of OPZELURA in patients with an active, serious infection, including localized infections. If a serious infection develops, interrupt OPZELURA until the infection is controlled. The risks and benefits of treatment with OPZELURA should be carefully...

What it is approved for

From the label in effect Jun 30, 2026.

OPZELURA is a Janus kinase (JAK) inhibitor indicated for: the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ( 1.1 ) the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. ( 1.2 ) Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended. ( 1.3 ) 1.1 Atopic Dermatitis OPZELURA is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 1.2 Nonsegmental Vitiligo OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. 1.3 Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.

Mechanism: Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 18, 2025 Supplement 7 · Efficacy LetterLabel
  • Jul 18, 2022 Supplement 1 · Efficacy · priority review LetterLabelReview
  • Sep 21, 2021 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelLetterReviewLabel
1 products under this application
  • OPZELURA · RUXOLITINIB PHOSPHATE EQ 1.5% BASE · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ruxolitinib" as an intervention, any sponsor and status, largest first.

All 453 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,316
  • drug ineffective1,422
  • product use in unapproved indication859
  • death797
  • anaemia742
  • pyrexia618
  • pneumonia589
  • thrombocytopenia564
  • platelet count decreased536
  • pruritus517
  • haemoglobin decreased511
  • fatigue462

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201211
201314
201422
201553
2016104
2017209
2018299
2019336
2020530
20211,110
20221,775
20233,230
20242,774
20252,725
20262,121

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Opzelura (Ruxolitinib Phosphate)

2024 spending

$106M

Beneficiaries

19,146

50,464 claims

Per beneficiary

$5,531

$32.96 per unit

View as table
YearSpending
2020$0
2021$946,803
2022$24,255,429
2023$75,729,871
2024$105,903,177

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 398 on PubMed

Sponsor: Incyte

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.